Press releases
Stayble Therapeutics presents at Financial Stockholm’s investor meeting on September 25, 2023
Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company will participate in the investor meeting "Investera som proffsen," organized by Financial Stockholm...
Stayble Therapeutics announces final patient´s last visit in the Phase 2b clinical study
Stayble Therapeutics AB ("Stayble" or the "Company") today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc...
Stayble Therapeutics terminates agreement regarding liquidity provider
Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB ("Lago")....
First patient enrolled in Stayble Therapeutics’ Phase 1b clinical study in herniated discs
Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the first patient has been enrolled in the Company's Phase 1b clinical study with STA363...
Stayble Therapeutics publishes half-year report for 2023
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its half-year report for 2023. The report is available as an attached document and on the...
90% have completed 12-month follow-up in Stayble Therapeutics’ ongoing Phase IIb study
Stayble Therapeutics AB ("Stayble" or the "Company") announces that approximately 90% of all patients in the Company's ongoing Phase IIb study in degenerative disc disease...
Stayble Therapeutics visited the Bio International Convention in Boston
As part of Stayble Therapeutics’ (“Stayble”) strategy to find a development partner, the company participated in the international Bio International Convention in Boston last week....
(SE) Kommuniké från årsstämman i Stayble Therapeutics
Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma den 1 juni 2023 kl. 14.00 på Bolagets kontor på Arvid Hedvalls Backe 4 i Göteborg....
Stayble Therapeutics publishes interim report for the first quarter 2023
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the first quarter of 2023. The report is available as an attached...
(SE) Stayble Therapeutics publicerar årsredovisningen för 2022
Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2022. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.
Stayble Therapeutics terminates agreement regarding liquidity provider
Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB ("Lago")....
Stayble Therapeutics publishes half-year report for 2023
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its half-year report for 2023. The report is available as an attached document and on the...
(SE) Kommuniké från årsstämman i Stayble Therapeutics
Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma den 1 juni 2023 kl. 14.00 på Bolagets kontor på Arvid Hedvalls Backe 4 i Göteborg....
Stayble Therapeutics publishes interim report for the first quarter 2023
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the first quarter of 2023. The report is available as an attached...
(SE) Stayble Therapeutics publicerar årsredovisningen för 2022
Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2022. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.